Quick Answer
Lyra Therapeutics, Inc. reported Total Revenue of $398.0 thousand for the year ending 2025.
- Lyra Therapeutics, Inc. showed a decrease of -74.1% in Total Revenue from 2024 to 2025.
- This data is from Lyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $14.0 thousand | Q1 2022: $468.0 thousand | Q2 2022: $525.0 thousand | Q3 2022: $359.0 thousand | Q1 2023: $410.0 thousand | Q2 2023: $458.0 thousand | Q3 2023: $544.0 thousand | Q1 2024: $532.0 thousand | Q2 2024: $598.0 thousand | Q3 2024: $195.0 thousand | Q1 2025: $183.0 thousand | Q2 2025: $183.0 thousand | Q3 2025: $25.0 thousand.
- Over the full 5 years of available data (2021 to 2025), Lyra Therapeutics, Inc.'s Total Revenue has grown by 39.6%.
- Historical annual values: Fiscal year 2025: $398.0 thousand | Fiscal year 2024: $1.53 million | Fiscal year 2023: $1.56 million | Fiscal year 2022: $1.36 million | Fiscal year 2021: $285.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: